Tem­pest eyes piv­otal tri­al for liv­er can­cer drug af­ter un­veil­ing ear­ly PFS, OS da­ta

Months af­ter ini­tial da­ta sug­gest­ed Tem­pest Ther­a­peu­tics’ drug, when giv­en on top of Roche’s Avastin and Tecen­triq, can help shrink liv­er can­cer, the com­pa­ny is back with a first glance at pro­gres­sion-free sur­vival and over­all sur­vival da­ta in a Phase Ib/II tri­al.

The com­bi­na­tion of Avastin and Tecen­triq is the cur­rent stan­dard of care in first-line liv­er can­cer, ac­cord­ing to Tem­pest. In the tri­al, 40 pa­tients re­ceived a triplet ther­a­py — in­clud­ing TPST-1120, Tem­pest’s PPAR⍺ an­tag­o­nist — while an­oth­er 30 re­ceived Avastin and Tecen­triq.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER